Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.
Actively Recruiting
Researchers are studying the impact and burden of three skin conditions moderate or severe alopecia areata, non-segmental vitiligo, and moderate to severe hidradenitis suppurativa. The study includes adolescents and adults and aims to understand how these conditions affect quality of life and daily functioning in a large global population. This is an observational study where participants with each condition will have a single visit for data collection following routine clinical practice. No experimental treatments are given instead, the study gathers information during this one visit to assess disease characteristics and impact. During the visit, participants will complete questionnaires and clinical assessments specific to their condition. These include tools measuring symptom impact, hair loss severity, skin depigmentation, and quality of life related to each disease. This helps researchers better understand the real-world burden of these conditions. Participation involves only this one visit, with no long-term follow-up or additional procedures.
Actively Recruiting
This research aims to gather detailed data and biomaterials from adults diagnosed with Acute Lymphoblastic Leukemia ALL and related diseases, including certain types of Leukemia and Non-Hodgkins Lymphoma. The registry supports ALL research and quality assurance by collecting information regardless of whether patients participate in clinical trials. The study is observational and involves adults diagnosed and treated under ALL protocols. Participants include adults aged 18 and older with ALL subtypes, other leukemias treated according to ALL protocols, and specific subtypes of Non-Hodgkins Lymphoma treated under B-ALL protocols. The study collects data prospectively on diagnosis, treatment, and outcomes, along with biomaterials related to these conditions. Participants provide information during routine clinical care and follow-up visits for up to 10 years. Data collected includes survival rates, remission status assessed by various methods including PET scans, relapse rates, quality of life questionnaires, and monitoring of toxicities and comorbidities. The study tracks overall survival and other outcomes over long-term follow-up to support research and quality assurance in adult ALL and related diseases.
Actively Recruiting
Researchers are evaluating the impact of standardized patient coaching on how consistently patients with hormone receptor-positive, HER2-negative early breast cancer take abemaciclib, a prescribed oral therapy. The study aims to find out if coaching based on a recognized teaching tool improves treatment adherence compared to routine care. Participants will provide information through several questionnaires to help answer this question. Participants receive standardized coaching based on the Multinational Association of Supportive Care in Cancer MASCC Oral Agent Teaching Tool MOATT. The coaching is designed to support patients while they take abemaciclib combined with endocrine therapy. The study follows patients for up to one year or until they stop taking abemaciclib permanently, whichever comes first. During the study, participants will complete questionnaires measuring their satisfaction with medicine information, medication adherence, and patient typology at 6 and 12 months after starting therapy. Researchers will monitor the time until patients discontinue abemaciclib as the main outcome. The study includes ongoing assessments to understand how coaching affects treatment persistence and patient experience over the year-long period.
Actively Recruiting
Researchers are evaluating whether a preference-oriented quality of life QoL monitoring system with specific diagnostic and therapeutic options can improve the well-being of patients with lung cancer during routine follow-up care. This study builds on successful QoL interventions for breast and colorectal cancer and aims to adapt the system for lung cancer patients in multiple centers. The study uses electronic QoL questionnaires and links patient data with a cancer registry to support analysis. Participants are randomly assigned to one of two groups. The intervention group receives real-time results from an electronic QoL monitoring system based on the EORTC QLQ-C30 and QLQ-LC29 questionnaires, along with access to a multiprofessional network of therapists such as pain therapy, psychotherapy, social support, nutrition counseling, physiotherapy, fitness, respiratory therapy, and palliative care. The control group also completes QoL assessments but neither patients nor their physicians receive the results however, the therapist network is available for both groups. QoL is assessed at study entry and monthly for six months. Throughout the six-month follow-up, participants complete QoL questionnaires at baseline and monthly intervals. Researchers monitor the proportion of patients needing QoL therapy based on a profile with eight dimensions, with a focus on whether the intervention reduces this need after six months. Data collection includes linking clinical information from a cancer registry. The study involves multiple assessments, therapeutic referrals, and ongoing monitoring to evaluate quality of life improvements in lung cancer patients.
Actively Recruiting
Researchers are conducting a multi-center, prospective, non-interventional study in Germany to collect real-world clinical and patient-reported data from women with primary advanced FIGO stage III or IV or recurrent endometrial cancer receiving first-line treatment. The study evaluates two maintenance therapies following chemotherapy with Carboplatin, Paclitaxel, and Durvalumab CPD, focusing on outcomes in patients with different tumor DNA mismatch repair statuses. The goal is to understand the effectiveness, safety, and patient experiences with these treatments in routine clinical practice. Participants receive first-line CPD chemotherapy. Those with DNA mismatch repair deficient tumors dMMR cohort receive maintenance therapy with durvalumab alone if their disease is controlled after chemotherapy. Participants with DNA mismatch repair proficient tumors pMMR cohort receive maintenance therapy with durvalumab and olaparib under similar conditions. Treatment decisions are based on standard care guidelines and made jointly by patients and their physicians. The study follows patients over time to observe treatment duration and transitions. During the study, participants complete patient-reported outcome questionnaires to assess quality of life and symptom changes after chemotherapy. Clinical data including time to next treatment and progression-free survival are collected up to 46 months. The study also tracks maintenance therapy duration, chemotherapy duration, and timing between chemotherapy and maintenance start. Safety and treatment use are monitored as part of routine care. Overall, the study provides long-term real-world insights into first-line and maintenance therapy for endometrial cancer.
Actively Recruiting
Researchers are observing patients with documented HER2-positive, HER2-low, or HER2-ultralow unresectable or metastatic breast cancer who are receiving trastuzumab deruxtecan T-DXd treatment. The study evaluates patient-reported outcomes as well as real-world effectiveness and safety of T-DXd when used according to the approved product guidelines within routine clinical practice in Germany. Additionally, patients will be informed about using a digital healthcare application DiGA. Participants receive T-DXd treatment as part of their routine care, with no specific treatment schedule dictated by the study protocol. The study includes two groups one with HER2-positive breast cancer patients and another with HER2-low or HER2-ultralow patients, each group expected to enroll approximately 400 participants. All diagnostic and treatment decisions, including visit frequency, are managed by the treating physician. During the study, participants health and treatment progress will be tracked, including patient-reported quality of life assessments using FACT-B and FACT-G questionnaires at six months. Researchers will monitor the time from first T-DXd dose to the next treatment or death, assessed for up to 60 months. The study lasts until December 2031, with ongoing observation of real-world treatment outcomes and safety.
Actively Recruiting
Plaque psoriasis is a chronic inflammatory skin condition that causes thick, red, and scaly patches. This research evaluates how treatment with risankizumab affects the quality of life in adults with moderate to severe plaque psoriasis in real-world clinical settings. About 700 participants prescribed risankizumab by their doctors according to local guidelines will be involved in this study. Participants will receive risankizumab as directed by their physicians based on routine care and local labeling. There are no additional treatments or study drugs provided beyond what is normally prescribed. The study is observational and follows participants for up to 2.5 years while they continue their usual treatment. During the study, participants will attend regular visits at hospitals or clinics as part of their standard care. Researchers will assess outcomes such as the proportion of participants achieving a Dermatology Life Quality Index DLQI score of 0 or 1 at 12 months. The study aims to understand the impact of risankizumab on quality of life with minimal extra burden to participants.